UNDER OECD GUIDELINES, ALBINO MICE ANIMAL STUDIES TO STANDARDISE PZ DRUG AGAINST THE REFRACTORY SPIKE PROTEIN INFECTION, HOMO SAPIENS SKIN DEPIGMENTARY DISORDER, CANCER (ALL) AND HENSEN PROBLEM

Human system is a bio-automation and self- repairing. The four diseases in reference: spike protein infection, Homo sapien skin depigmentary disorder, cancer and Hensen problem which have varying root cause, are exceptional. Complementary characteristics of spike protein, human protein and PZ drug led to the development of Principles I whereas principles 2, is based upon the epidermal photosensitivity of PZ drug. Principle I fit the bill of treatment of Homo sapien skin depigmentary disorder, while Principle 2 applies for other diseases. Additionally Albino mice animal study is equally significant and promising. The cage side observations show no toxicity from 0.5 g and 1 g of drug treatment. The acute toxicity and sub toxicity study show that the body weight of each sex was significantly (p<0.001) increased in both groups. The organal histopathology (brain, heart, kidney, liver) at 0.5 g and 1.0 g treatment has resulted in normal histopathology status. The biochemistry of Albino mice showed no significant changes in any of the biochemical parameters when compared with the central group. The above data and discussion would lead us to the easy and safe, human trials at 0.5 and 1.0 g drug levels and treatments of the four diseases in reference with PZ drug.